Primary Care Considerations of the Pharmacokinetics and Clinical Use of Extended-Release Opioids in Treating Patients with Chronic Noncancer Pain

References

• . Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education and Research. Washington. DC: The National Academies Press; 2011
   Google Scholar
• . National Center for Health Statistics. Health, United States, 2006 With Chartbook on Trends in the Health of Americans. Hyattsville, MD: Centers for Disease Control and Prevention; 2006. http://www.cdc.gov/nchs/data/hus/hus06.pdf Accessed September 23, 2011
   Google Scholar
• . Jackman RP, Purvis JM, Mallett BS. Chronic nonmalignant pain in primary care. Am Fam Physician. 2008;78(10):1155–1162
   PubMed Web of Science ®Google Scholar
• . Nicholson B. Benefits of extended-release opioid analgesic formulations in the treatment of chronic pain. Pain Pract. 2009;9(1):71–81
   PubMed Web of Science ®Google Scholar
• . McCarberg BH, Nicholson BD, Todd KH, Palmer T, Penles L. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an internet survey. Am J Ther. 2008;15(4):312–320
   PubMed Web of Science ®Google Scholar
• . Chou R, Fanciullo GJ, Fine PG, . Opioid treatment guidelines: clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–130
   PubMed Web of Science ®Google Scholar
• . Trescot AM, Helm S, Hansen H, . Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008;11 ( 2 suppl):S5–S62
   PubMed Web of Science ®Google Scholar
• . Rauck RL. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract. 2009;9(6):468–479
   PubMedGoogle Scholar
• . Moore KT, St—Fleur D, Marricco NC, . Steady-state pharmacokinetics of extended-release hydromorphone (OROS hydromorphone): a randomized study in healthy volunteers. J Opioid Manag. 2010;6(5):351–358
   PubMedGoogle Scholar
• . Exalgo [package insert]. Hazelwood, MO: Mallinckrodt Brand Pharmaceuticals, Inc.; 2012
   Google Scholar
• . Avinza [package insert]. Bristol, TN: King Pharmaceuticals, Inc; 2008
   Google Scholar
• . Kadian [package insert]. Morristown, NJ: Actavis Elizabeth LLC; 2010
   Google Scholar
• . MS Contin [package insert]. Stamford, CT: Purdue Pharma L.P.; 2009
   Google Scholar
• . Oramorph SR [package insert]. Newport, KY: Xanodyne Pharmaceuticals, Inc; 2006
   Google Scholar
• . Embeda [package insert]. Bristol, TN: King Pharmaceuticals; 2009
   Google Scholar
• . OxyContin [package insert]. Stamford, CT: Purdue Pharma L.P.; 2011
   Google Scholar
• . OpanaER [package insert]. Chadds Ford, PA: Endo Pharmaceuticals, Inc; 2008
   Google Scholar
• . Nucynta ER [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc; 2011
   Google Scholar
• . Butrans [package insert]. Stamford, CT: Purdue Pharma L.P.; 2010
   Google Scholar
• . Duragesic [package insert]. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; 2011
   Google Scholar
• . US Food and Drug Administration. Enforcement Report for June 9, 2010. Recalls and Field Corrections: Drugs—Class III. http://www.fda.gov/Safety/Recalls/EnforcementReports/ucm214953.htm. Accessed October 15, 2012
   Google Scholar
• . Fine PG, Mahajan G, McPherson ML. Long-acting opioids and short-acting opioids: appropriate use in chronic pain management. Pain Med. 2009;10( suppl 2):S79–S88
   PubMed Web of Science ®Google Scholar
• . Pergolizzi JV Jr, Taylor R Jr, Raffa RB. Extended-release formulations of tramadol in the treatment of chronic pain. Expert Opin Pharmacother. 2011;12(11):1757–1768
   PubMed Web of Science ®Google Scholar
• . Substance Abuse and Mental Health Services Administration. Results From the 2010 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2011. NSDUH Series H-41, HHS Publication No. (SMA) 11–4658. http://samhsa.gov/data/NSDUH/2k10NSDUH/2k10Results.htm. Published September 2011. Accessed March 20, 2012
   Google Scholar
• . Centers for Disease Control and Prevention. Unintentional drug poisoning in the United States. http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf Published July 2010. Accessed May 30, 2012
   Google Scholar
• . Governale L. Outpatient presciption opioid utilization in the US, years 2000–2009. US Food and Drug Administration; July 22, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM220950.pdf Accessed June 27, 2011
   Google Scholar
• . Caudill—Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs 2000. Pain. 2004;109(3):514–519
   PubMed Web of Science ®Google Scholar
• . Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by U.S. primary care physicians from 1992 to 2001. J Pain. 2006;7(4):225–235
   PubMed Web of Science ®Google Scholar
• . Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain. 2007;8(7):573–582
   PubMed Web of Science ®Google Scholar
• . Fleming MF, Davis J, Passik SD. Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients. Pain Med. 2008;9(8):1098–1106
   PubMed Web of Science ®Google Scholar
• . Potter M, Schafer S, Gonzalez—Mendez E, . Opioids for chronic nonmalignant pain. Attitudes and practices of primary care physicians in the UCSF/Stanford Collaborative Research Network. University of California, San Francisco. J Fam Pract. 2001;50(2):145–151
   PubMed Web of Science ®Google Scholar
• . Gourlay GK. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine. Clin Pharmacokinet. 1998;35(3):173–190
   PubMed Web of Science ®Google Scholar
• . Angst MS, Drover DR, Lotsch J, . Pharmacodynamics of orally administered sustained-release hydromorphone in humans. Anesthesiology. 2001;94(1):63–73
   PubMedGoogle Scholar
• . Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devane J. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J Pain Symptom Manage. 2002;23(4):292–300
   PubMedGoogle Scholar
• . Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol. 1996;42(6):747–756
   PubMed Web of Science ®Google Scholar
• . Shram MJ, Sathyan G, Khanna S, . Evaluation of the abuse potential of extended release hydromorphone versus immediate release hydromorphone. J Clin Psychopharmacol. 2010;30(1):25–33
   PubMed Web of Science ®Google Scholar
• . McCarberg BH, Barkin RL. Long-acting opioids for chronic pain: pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia. Am J Ther. 2001;8(3):181–186
   PubMedGoogle Scholar
• . Gupta S, Sathyan G. Providing consistent analgesia with OROS® hydromorphone. J Pain Symptom Manage. 2007;33( suppl 2):S19–S24
   Web of Science ®Google Scholar
• . Eliot L, Geiser R, Loewen G. Steady-state pharmacokinetic comparison of a new, once-daily extended-release morphine formulation (Morphelan™) and OxyContin® twice daily. J Oncol Pharm Pract. 2001;7(1):1–8
   Google Scholar
• . Amabile CM, Bowman BJ. Overview of oral modified-release opioid products for the management of chronic pain. Ann Pharmacother. 2006;40(7–8):1327–1335
   PubMedGoogle Scholar
• . Hagen NA, Thirlwell M, Eisenhoffer J, Quigley P, Harsanyi Z, Darke A. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain. J Pain Symptom Manage. 2005;29(1):80–90
   PubMedGoogle Scholar
• . Afilalo M, Etropolski MS, Kuperwasser B, . Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010;30(8):489–505
   PubMed Web of Science ®Google Scholar
• . Caldwell JR, Rapoport RJ, Davis JC, . Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J Pain Symptom Manage. 2002;23(4):278–291
   PubMed Web of Science ®Google Scholar
• . Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin. 2010;26(6):1505–1518
   PubMed Web of Science ®Google Scholar
• . Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled phase III trial. Pain Med. 2005;6(5):357–366
   PubMed Web of Science ®Google Scholar
• . Roth SH, Fleischmann RM, Burch FX, . Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med. 2000;160(6):853–860
   PubMedGoogle Scholar
• . Gordon A, Rashiq S, Moulin DE, . Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag. 2010;15(3):169–178
   PubMed Web of Science ®Google Scholar
• . Langford R, McKenna F, Ratcliffe S, Vojtassak J, Richarz U. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: a randomized, placebo-controlled trial. Arthritis Rheum. 2006;54(6):1829–1837
   PubMedGoogle Scholar
• . Carson S, Thakurta S, Low A, Smith B, Chou R. Drug Class Review: Long-Acting Opioid Analgesics. Update 6. Portland, OR: Oregon Health and Science University; 2011
   Google Scholar
• . Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R. A randomized study to demonstrate noninferiority of once-daily OROS® hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract. 2010;10(5):404–415
   PubMed Web of Science ®Google Scholar
• . Caldwell JR, Hale ME, Boyd RE, . Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999;26(4):862–869
   PubMed Web of Science ®Google Scholar
• . Hurley DA, Eadie J, O'Donoghue G, . Physiotherapy for sleep disturbance in chronic low back pain: a feasibility randomised controlled trial. BMC Musculoskelet Disord. 2010;11:70
   PubMedGoogle Scholar
• . O'Donoghue GM, Fox N, Heneghan C, Hurley DA. Objective and subjective assessment of sleep in chronic low back pain patients compared with healthy age and gender matched controls: a pilot study. BMC Musculoskelet Disord. 2009;10:122
   PubMed Web of Science ®Google Scholar
• . Chiu YH, Silman AJ, Macfarlane GJ, . Poor sleep and depression are independently associated with a reduced pain threshold. Results of a population based study. Pain. 2005;115(3):316–321
   PubMed Web of Science ®Google Scholar
• . Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988;15(12):1833–1840
   PubMed Web of Science ®Google Scholar
• . Wallace M, Thipphawong J. Open-label study on the long-term efficacy, safety, and impact on quality of life of OROS hydromorphone ER in patients with chronic low back pain. Pain Med. 2010;11(10):1477–1488
   PubMedGoogle Scholar
• . Won A, Lapane KL, Vallow S, Schein J, Morris JN, Lipsitz LA. Long-term effects of analgesics in a population of elderly nursing home residents with persistent nonmalignant pain. J Gerontol A Biol Sci Med Sci. 2006;61(2):165–169
   PubMedGoogle Scholar
• . Mordarski S, Lysenko L, Gerber H, Zietek M, Gredes T, Dominiak M. The effect of treatment with fentanyl patches on pain relief and improvement in overall daily functioning in patients with postherpetic neuralgia. J Physiol Pharmacol. 2009;60( suppl 8):31–35
   PubMed Web of Science ®Google Scholar
• . James IG, O'Brien CM, McDonald CJ. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans® seven-day patches) with buprenorphine sublingual tablets (Temgesic®) in patients with osteoarthritis pain. J Pain Symptom Manage. 2010;40(2):266–278
   PubMed Web of Science ®Google Scholar
• . Gatti A, Dauri M, Leonardis F, . Transdermal buprenorphine in non-oncological moderate-to-severe chronic pain. Clin Drug Investig. 2010;30( suppl 2):31–38
   PubMed Web of Science ®Google Scholar
• . Smith H, Bruckenthal P. Implications of opioid analgesia for medically complicated patients. Drugs Aging. 2010;27(5):417–433
   PubMed Web of Science ®Google Scholar
• . Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613–624
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Information for healthcare professionals: methadone hydrochloride. US Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142841.htm. Published November 2006. Updated February 17, 2010. Accessed May 28, 2012
   Google Scholar
• . Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther. 1999;289(2):1048–1053
   PubMed Web of Science ®Google Scholar
• . Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38(3):426–439
   PubMed Web of Science ®Google Scholar
• . Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999–2006. NCHS Data Brief. 2009;22:1–8
   PubMedGoogle Scholar
• . Prodduturi S, Sadrieh N, Wokovich AM, Doub WH, Westenberger BJ, Buhse L. Transdermal delivery of fentanyl from matrix and reservoir systems: effect of heat and compromised skin. J Pharm Sci. 2010;99(5):2357–2366
   PubMed Web of Science ®Google Scholar
• . Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain. 2006;7(9):671–681
   PubMed Web of Science ®Google Scholar
• . Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360–372
   PubMed Web of Science ®Google Scholar
• . Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–442
   PubMed Web of Science ®Google Scholar
• . Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med. 2005;6(2):107–112
   PubMed Web of Science ®Google Scholar
• . Back SE, Lawson KM, Singleton LM, Brady KT. Characteristics and correlates of men and women with prescription opioid dependence. Addict Behav. 2011;36(8):829–834
   PubMed Web of Science ®Google Scholar
• . Passik SD, Weinreb HJ. Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther. 2000;17(2):70–83
   PubMed Web of Science ®Google Scholar
• . American Academy of Pain Medicine; American Pain Society; American Society of Addiction Medicine. Consensus document: definitions related to the use of opioids for the treatment of pain. WMJ. 2001;100(5):28–29
   PubMedGoogle Scholar
• . Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs. 2009;18(3):255–263
   PubMed Web of Science ®Google Scholar
• . Comer SD, Ashworth JB, Sullivan MAVosburg SK, Saccone PA Foltin RW. Relationship between rate of infusion and reinforcing strength of oxycodone in humans. J Opioid Manag. 2009;5(4):203–212
   PubMedGoogle Scholar
• . Butler SF, Fernandez KC, Chang A, . Measuring attractiveness for abuse of prescription opioids. Pain Med. 2010;11(1):67–80
   PubMed Web of Science ®Google Scholar
• . Setnik B, Roland CL, Cleveland JM, Webster L. The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011;12(4):618–631
   PubMed Web of Science ®Google Scholar
• . Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164(11):1750–1756
   PubMed Web of Science ®Google Scholar
• . Hays LR. A profile of OxyContin addiction. J Addict Dis. 2004;23(4):1–9
   PubMed Web of Science ®Google Scholar
• . McCabe SE, Cranford JA, Boyd CJ, Teter CJ. Motives, diversion and routes of administration associated with nonmedical use of prescription opioids. Addict Behav. 2007;32(3):562–575
   PubMed Web of Science ®Google Scholar
• . Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20(2):5–13
   PubMedGoogle Scholar
• . US Food and Drug Administration. Questions and answers: FDA requires a risk evaluation and mitigation strategy (REMS) for long-acting and extended-release opioids. US Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm251752.htm. Updated April 19, 2011. Accessed July 29, 2011
   Google Scholar
• . Nelson L, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol. 2009;5(4):230–241
   PubMedGoogle Scholar
• . Marquardt KA, Tharratt RS, Musallam NA. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother. 1995;29(10):969–971
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Disposal of unused medicines: what you should know. US Food and Drug Administration website. http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/EnsuringSafeUseofMedicine/SafeDisposalofMedicines/ucm186187.htm. Updated September 25, 2012. Accessed October 19, 2012
   Google Scholar
• . FDA introduces new safety measures for extended-release and long-acting opioid medications [press release]. Silver Spring, MD: US Department of Health and Human Services, US Food and Drug Administration; July 9, 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm. Accessed July 9, 2012
   Google Scholar
• . US Department of Health and Human Services; US Food and Drug Administration. Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). Published July 9, 2012. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf Accessed October 15, 2012
   Google Scholar
• . US Department of Health and Human Services; US Food and Drug Administration. Post-approval REMS notification letter. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM251595.pdf Accessed July 13, 2012
   Google Scholar
• . US Department of Health and Human Services; US Food and Drug Administration. Blueprint for prescriber continuing education program. July 9, 2012. http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM277916.pdf Accessed October 15, 2012
   Google Scholar
• . Patient counseling document. ER/LA Opioid REMS website, http://www.er-la-opioidrems.com/IwgUI/rems/pcd.action. Accessed January 14, 2013
   Google Scholar
• . Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access Home. https://www.tirfremsaccess.com/TirfUI/rems/home.action. Accessed October 15, 2012
   Google Scholar